Literature DB >> 15712659

Osteopontin expression in proliferated bile ductules: the correlation with liver damage in fulminant hepatitis.

Takuma Tajiri1, Genshu Tate, Toshiaki Kunimura, Yutaka Endo, Kazuaki Inoue, Toshiyuki Mitsuya, Toshio Morohoshi, Makoto Yoshiba.   

Abstract

There have been many reports about the severity of hepatic necrosis caused by fulminant hepatitis; however, the relation between proliferated bile ductules and osteopontin (OPN) expression in inflamed areas in each of the clinical forms of fulminant hepatitis has not been described. To analyze the mechanism in the onset of fulminant hepatitis, we classified not only 16 autopsy cases of fulminant hepatitis into two clinical forms--acute and subacute--but also 3 autopsy cases of late-onset hepatic failure (LOHF) associated with fulminant hepatitis, and examined liver specimens by light microscopy and immunohistochemistry and also serum transaminase levels. Histopathologic study revealed that some of the proliferated bile ductules were associated directly with deteriorating hepatocytes and that bile plugs were present in the proliferated bile ductules. The value of the proliferative cell nuclear antigen labeling index (PCNA-L I) for proliferated bile ductules was very high during the acute form of fulminant hepatitis. Immunohistochemical analysis revealed that OPN expression was higher in the proliferated bile ductules of acute-form fulminant hepatitis than in cirrhotic and normal liver bile ducts. Transaminase levels in acute-form fulminant hepatitis were significantly elevated in comparison with levels in the other forms of the disease. Comparison of acute form fulminant hepatitis with the subacute form and LOHF showed OPN expression in proliferated bile ductules and serum aspartate aminotransferase (ALT)max to be decreased in the subacute form of fulminant hepatitis. OPN expression is an important marker of the degree of liver inflammation, and its regulation mechanism is very important to understanding the pathophysiology of fulminant hepatitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712659     DOI: 10.1007/s10620-005-1299-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

Review 2.  [Fulminant hepatitis and late onset hepatic failure (LOHF) in Japan].

Authors:  Satoshi Mochida; Kenji Fujiwara
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  2002-08

3.  Clinical and molecular virological differences between fulminant hepatic failures following acute and chronic infection with hepatitis B virus.

Authors:  K Inoue; M Yoshiba; K Sekiyama; H Okamoto; M Mayumi
Journal:  J Med Virol       Date:  1998-05       Impact factor: 2.327

4.  Late onset hepatic failure: clinical, serological and histological features.

Authors:  A E Gimson; J O'Grady; R J Ede; B Portmann; R Williams
Journal:  Hepatology       Date:  1986 Mar-Apr       Impact factor: 17.425

5.  The nature and origin of proliferated bile ductules in alcoholic liver disease.

Authors:  T Uchida; R L Peters
Journal:  Am J Clin Pathol       Date:  1983-03       Impact factor: 2.493

6.  Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas.

Authors:  R Kawashima; S Mochida; A Matsui; Y YouLuTuZ; K Ishikawa; K Toshima; F Yamanobe; M Inao; H Ikeda; A Ohno; S Nagoshi; T Uede; K Fujiwara
Journal:  Biochem Biophys Res Commun       Date:  1999-03-24       Impact factor: 3.575

7.  The development of proliferating ductular structures in liver disease. An immunohistochemical study.

Authors:  S N Thung
Journal:  Arch Pathol Lab Med       Date:  1990-04       Impact factor: 5.534

8.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

9.  Macrophages express osteopontin during repair of myocardial necrosis.

Authors:  C E Murry; C M Giachelli; S M Schwartz; R Vracko
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

10.  Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis.

Authors:  Kenichi Harada; Satoru Ozaki; Yoshiko Sudo; Koichi Tsuneyama; Hajime Ohta; Yasuni Nakanuma
Journal:  Pathol Int       Date:  2003-01       Impact factor: 2.534

View more
  5 in total

Review 1.  Comparative analysis of gene expression profiles of OPN signaling pathway in four kinds of liver diseases.

Authors:  Gaiping Wang; Shasha Chen; Congcong Zhao; Xiaofang Li; Weiming Zhao; Jing Yang; Cuifang Chang; Cunshuan Xu
Journal:  J Genet       Date:  2016-09       Impact factor: 1.166

2.  A preliminary in vivo study of the effects of OPN on rat liver regeneration induced by partial hepatectomy.

Authors:  Gaiping Wang; Congcong Zhao; Shasha Chen; Xiaofang Li; Ling Zhang; Cuifang Chang; Cunshuan Xu
Journal:  Mol Biol Rep       Date:  2016-09-01       Impact factor: 2.316

3.  Serum osteopontin is a predictor of prognosis for HBV-associated acute-on-chronic liver failure.

Authors:  Longgen Liu; Jianchun Lu; Chunyan Ye; Lin Lin; Shuqin Zheng; Hongyu Zhang; Qing Lan; Yuan Xue
Journal:  Biomed Rep       Date:  2017-12-13

4.  Osteopontin Expression in Patients with Hepatolith.

Authors:  Bum Soo Kim; Sun Hyung Joo; Sung Jig Lim; Kwang Ro Joo
Journal:  Indian J Surg       Date:  2013-05-18       Impact factor: 0.656

Review 5.  Role of Osteopontin in Liver Diseases.

Authors:  Yankai Wen; Seogsong Jeong; Qiang Xia; Xiaoni Kong
Journal:  Int J Biol Sci       Date:  2016-08-06       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.